1.A response to the letter regarding “Minimally invasive surgery for remnant gastric cancer: a single-center retrospective study of treatment outcomes in Japan”
Kenichi IWASAKI ; Edward BARROGA ; Yoichiro KANEKO ; Shohei KONDO ; Toru SAKURAI ; Erika YAMADA ; Masaya ENOMOTO ; Yota SHIMODA ; Kenta KASAHARA ; Hiroaki OSAKABE ; Junichi MAZAKI ; Hiroshi KUWABARA ; Junya OGUMA ; Hiroyuki KOGA ; Akishige KANAZAWA ; Yuichi NAGAKAWA
Journal of Minimally Invasive Surgery 2026;29(2):115-116
2.Minimally invasive surgery for remnant gastric cancer:a single-center retrospective study of treatment outcomes in Japan
Kenichi IWASAKI ; Edward BARROGA ; Yoichiro KANEKO ; Shohei KONDO ; Toru SAKURAI ; Erika YAMADA ; Masaya ENOMOTO ; Yota SHIMODA ; Kenta KASAHARA ; Hiroaki OSAKABE ; Junichi MAZAKI ; Hiroshi KUWABARA ; Junya OGUMA ; Hiroyuki KOGA ; Akishige KANAZAWA ; Yuichi NAKAGAWA
Journal of Minimally Invasive Surgery 2026;29(1):11-21
Purpose:
Surgical resection of remnant gastric cancer (RGC) is technically challenging and difficult. Minimally invasive surgery (MIS) has been adopted for various procedures, but reports of MIS for RGC remain limited. Herein, we report the surgical techniques and short-term outcomes of MIS for RGC.
Methods:
We conducted a retrospective cohort study involving 61 consecutive RGC patients who underwent open or minimally invasive (laparoscopic or robotic) total gastrectomy for potentially curable RGC at our institution (January 1999–August 2025). A propensity scorematched cohort was used for an exploratory evaluation of the safety and efficacy of MIS for RGC, focusing on feasibility rather than superiority over open surgery.
Results:
Of these 61 patients, 53 underwent open surgery and eight underwent MIS gastrectomy for RGC. The median age was 70 years. The cohort comprised 53 men and eight women. The initial procedure was open surgery in 58 patients and MIS in three patients.Propensity score matching showed significantly reduced intraoperative blood loss in the MIS group compared with the open surgery group (39 mL vs. 576 mL, p < 0.05), and significantly longer operation time in the MIS group (352 minutes vs. 297 minutes, p < 0.05). Postoperative hospital stay was significantly shorter in the MIS group (12 days vs. 17 days, p < 0.05). The incidence of postoperative pancreatic fistula was lower in the MIS group, although not significantly different (0% vs. 16.7%).
Conclusion
MIS, including robotic gastrectomy, is feasible and safe for RGC, with potential perioperative benefits requiring multicenter validation.
3.A Case of a Peritoneal Dialysis Patient Who Underwent OPCAB for Acute Coronary Syndromes after Debranching TEVAR
Kazuki TAMURA ; Yasuyuki YAMADA ; Masahiko EZURE ; Yutaka HASEGAWA ; Joji HOSHINO ; Shuichi OKADA ; Yoshifumi ITODA ; Hiroyuki MORISHITA ; Masahiro SEKI ; Takashi SODA
Japanese Journal of Cardiovascular Surgery 2025;54(2):49-52
An 82-year-old male patient who had a history of ischemic heart disease (IHD) and Debranching Thoracic Endovascular Aortic Repair (TEVAR) (right axillary artery-left axillary artery-left common carotid artery) was admitted to our hospital due to sudden chest pain. The diagnosis revealed acute coronary syndrome: 2-vessel lesions, including the left main trunk (LMT) (right coronary artery (RCA) #2 75%, #3 90%, LMT #5 50%, and left anterior descending (LAD) branch #7 75%). Plain Old Balloon Angioplasty (POBA) was performed on the responsible lesion, RCA (#2-3). Off-pump Coronary Artery Bypass Grafting (OPCAB) was initially planned for the remaining lesion. However, cardiogenic shock occurred, and an emergency OPCAB (SVG-LAD, SVG-#4PD) was performed via partial sternotomy (inverted L-shaped incision on the left side), using intra-aortic balloon pumping (IABP). The patient underwent revascularization using great saphenous vein grafts due to the potential for postoperative pleuroperitoneal communication in patients undergoing peritoneal dialysis, as well as the risk of impaired internal thoracic artery (ITA) flow caused by debranching in future involving internal shunts for dialysis. It is important to consider not only the graft but also the thoracotomy, taking into account the perspectives of early weaning and the prevention of perioperative complications.
4.Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy
Kazuya INOKI ; Seiichiro ABE ; Yusaku TANAKA ; Koji YAMAMOTO ; Daisuke HIHARA ; Ryoji ICHIJIMA ; Yukihiro NAKATANI ; HsinYu CHEN ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Taku SAKAMOTO ; Satoru NONAKA ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Ichiro ODA ; Takahisa MATSUDA ; Yutaka SAITO
Clinical Endoscopy 2021;54(3):363-370
Background/Aims:
Probe-based confocal laser endomicroscopy (pCLE) requires the administration of intravenous (IV) fluorescein. This study aimed to determine the optimal dose of IV fluorescein for both upper and lower gastrointestinal (GI) tract pCLE.
Methods:
Patients 20 to 79 years old with gastric high-grade dysplasia (HGD) or colorectal neoplasms (CRNs) were enrolled in the study. The dose de-escalation method was employed with five levels. The primary endpoint of the study was the determination of the optimal dose of IV fluorescein for pCLE of the GI tract. The reduced dose was determined based on off-line reviews by three endoscopists. An insufficient dose of fluorescein was defined as the dose of fluorescein with which the pCLE images were not deemed to be visible. If all three endoscopists determined that the tissue structure was visible, the doses were de-escalated.
Results:
A total of 12 patients with gastric HGD and 12 patients with CRNs were enrolled in the study. Doses were de-escalated to 0.5 mg/kg of fluorescein for both non-neoplastic duodenal and colorectal mucosa. All gastric HGD or CRNs were visible with pCLE with IV fluorescein at 0.5 mg/kg.
Conclusions
In the present study, pCLE with IV fluorescein 0.5 mg/kg was adequate to visualize the magnified structure of both the upper and lower GI tract.
5.Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy
Kazuya INOKI ; Seiichiro ABE ; Yusaku TANAKA ; Koji YAMAMOTO ; Daisuke HIHARA ; Ryoji ICHIJIMA ; Yukihiro NAKATANI ; HsinYu CHEN ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Taku SAKAMOTO ; Satoru NONAKA ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Ichiro ODA ; Takahisa MATSUDA ; Yutaka SAITO
Clinical Endoscopy 2021;54(3):363-370
Background/Aims:
Probe-based confocal laser endomicroscopy (pCLE) requires the administration of intravenous (IV) fluorescein. This study aimed to determine the optimal dose of IV fluorescein for both upper and lower gastrointestinal (GI) tract pCLE.
Methods:
Patients 20 to 79 years old with gastric high-grade dysplasia (HGD) or colorectal neoplasms (CRNs) were enrolled in the study. The dose de-escalation method was employed with five levels. The primary endpoint of the study was the determination of the optimal dose of IV fluorescein for pCLE of the GI tract. The reduced dose was determined based on off-line reviews by three endoscopists. An insufficient dose of fluorescein was defined as the dose of fluorescein with which the pCLE images were not deemed to be visible. If all three endoscopists determined that the tissue structure was visible, the doses were de-escalated.
Results:
A total of 12 patients with gastric HGD and 12 patients with CRNs were enrolled in the study. Doses were de-escalated to 0.5 mg/kg of fluorescein for both non-neoplastic duodenal and colorectal mucosa. All gastric HGD or CRNs were visible with pCLE with IV fluorescein at 0.5 mg/kg.
Conclusions
In the present study, pCLE with IV fluorescein 0.5 mg/kg was adequate to visualize the magnified structure of both the upper and lower GI tract.
6.The association between overweight and prevalence of food allergy in Japanese children: a cross-sectional study.
Koichiro HAYASHI ; Hiromasa TSUJIGUCHI ; Daisuke HORI ; Yohei YAMADA ; Yukari SHIMIZU ; Thao Thi Thu NGUYEN ; Yuri HIBINO ; Yasuhiro KAMBAYASHI ; Akinori HARA ; Hiroyuki NAKAMURA
Environmental Health and Preventive Medicine 2021;26(1):44-44
BACKGROUND:
Food allergy (FA) is a common disease in children, and its prevalence has increased in developed countries. The impact of overweight on children health also becomes an important social problem. However, the relationship between overweight and FA is still unclear. We examined the association between overweight and the prevalence of FA among Japanese children.
METHODS:
We analyzed data obtained using a self-administered questionnaire from 1772 Japanese children. Weight groups according to body mass index cutoff points proposed by the International Obesity Task Force were used to create two groups: overweight and non-overweight. Children were separated into four age groups (3-6 years, 6-9 years, 9-12 years, and 12-15 years) to examine age differences. We performed univariate and multivariate logistic models to examine the association between overweight and FA.
RESULTS:
The prevalence of FA was significantly higher in boys (10.6%, p = 0.014) than girls (4.5%) and girls (7.9%, p = 0.012) than boys (2.5%) for 6-9 and 12-15 age groups, respectively. While the prevalence of FA was significantly higher in overweight than non-overweight girls (26.1%, p = 0.005) in the 12-15 age group, no significant difference was found in boys. In girls, overweight was significantly associated with FA after adjustment for age and asthma (odds ratio 1.99, 95% confidence interval 1.01-3.89, p = 0.046).
CONCLUSIONS
Our results showed that being overweight was significantly associated with a higher prevalence of FA in girls, but not in boys. Further prospective studies are necessary to find the causal relationship between overweight and FA.
Adolescent
;
Body Mass Index
;
Child
;
Child, Preschool
;
Cross-Sectional Studies
;
Female
;
Food Hypersensitivity/epidemiology*
;
Humans
;
Japan/epidemiology*
;
Male
;
Overweight/epidemiology*
;
Prevalence
;
Sex Factors
7.Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
Masakazu HATANO ; Ippei TAKEUCHI ; Kanade YAMASHITA ; Aoi MORITA ; Kaori TOZAWA ; Takashi SAKAKIBARA ; Genta HAJITSU ; Manako HANYA ; Shigeki YAMADA ; Nakao IWATA ; Hiroyuki KAMEI
Clinical Psychopharmacology and Neuroscience 2021;19(4):610-617
Objective:
To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations.
Methods:
We evaluated the patients’ satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows:age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month.
Results:
In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients.Patients who answered “Decided by consultation with physicians” had significantly higher satisfaction levels and DAI-10 scores compared to those who answered “Decided by physicians” (4.11 ± 0.77 vs. 3.80 ± 1.00, p = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, p < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, p < 0.001).
Conclusion
No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients’ individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.
8.Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms
Wataru YAMAGAMI ; Mikio MIKAMI ; Satoru NAGASE ; Tsutomu TABATA ; Yoichi KOBAYASHI ; Masanori KANEUCHI ; Hiroaki KOBAYASHI ; Hidekazu YAMADA ; Kiyoshi HASEGAWA ; Hiroyuki FUJIWARA ; Hidetaka KATABUCHI ; Daisuke AOKI
Journal of Gynecologic Oncology 2020;31(1):18-
9.Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
Hiroyuki KAMEI ; Hanae YAMADA ; Masakazu HATANO ; Manako HANYA ; Shigeki YAMADA ; Nakao IWATA
Clinical Psychopharmacology and Neuroscience 2020;18(1):159-163
In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
10.Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
Hiroyuki KAMEI ; Yuki HOMMA ; Ippei TAKEUCHI ; Genta HAJITSU ; Kaori TOZAWA ; Masakazu HATANO ; Aiko FUKUI ; Manako HANYA ; Shigeki YAMADA ; Nakao IWATA
Clinical Psychopharmacology and Neuroscience 2020;18(1):49-57
Objective:
To improve poor medication adherence in schizophrenic patients, long-acting injectable (LAI) antipsychotics are used. However, it has not yet become common in Japan. Recently, aripiprazole LAI was approved for alternative injection into the deltoid muscle in addition to the gluteal muscle. The acceptance for the proposal to switch from gluteal to deltoid injections of aripiprazole LAI was investigated.
Methods:
The subjects were 32 outpatients with schizophrenia who had continuously received aripiprazole LAI administration into the gluteal muscle for ≥ 6 months. In the patients who had continued deltoid injection for 3 months after switching, the changes in the pain and shame in comparison with gluteal injections were evaluated.
Results:
Switching to the deltoid injection was chosen by 17 out of 32 patients. Three months later, 9 patients were still receiving deltoid injections with highly rated satisfaction. The main reasons for switching to deltoid injections included the pain and shame associated with gluteal injections. The main reason for returning to the gluteal injection was the pain experienced from the injection in the deltoid.
Conclusion
The option to select the injected area was based on the amount of pain in the deltoid and gluteal sites, leading to the widespread use of aripiprazole LAI.


Result Analysis
Print
Save
E-mail